Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived A (Seite 3) | Diskussion im Forum
eröffnet am 15.01.20 11:44:07 von
neuester Beitrag 27.07.23 10:37:34 von
neuester Beitrag 27.07.23 10:37:34 von
Beiträge: 66
ID: 1.318.619
ID: 1.318.619
Aufrufe heute: 0
Gesamt: 3.575
Gesamt: 3.575
Aktive User: 0
ISIN: US00653A1079 · WKN: A14SUX · Symbol: 473A
1,0500
EUR
+0,96 %
+0,0100 EUR
Letzter Kurs 16:00:12 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 11,688 | +41,55 | |
| 2,5150 | +37,73 | |
| 2,9250 | +35,73 | |
| 1,0000 | +31,56 | |
| 3,8900 | +26,55 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0639 | -16,13 | |
| 1,5400 | -16,30 | |
| 0,5601 | -17,02 | |
| 7,5000 | -18,92 | |
| 0,5350 | -20,15 |
Beitrag zu dieser Diskussion schreiben
Feedback
Lesezeichen
Antwort auf Beitrag Nr.: 67.090.038 von Anmami am 18.02.21 20:05:48ADAP ist extrem volatil und man kann hier gut traden. Es ändert aber wenig an dem mittelfristigen Zielen. Das letzte KE Level sollte noch dieses Jahr machbar sein. Und das Engagement von Baker spricht mMn für sich.
JMO.
JMO.
Antwort auf Beitrag Nr.: 67.089.858 von bcgk am 18.02.21 19:59:09Ich dachte hier schweben Kursziele von 11dollar usw... oder liege ich da falsch?
Antwort auf Beitrag Nr.: 67.089.585 von Anmami am 18.02.21 19:47:51Habe heute zu $6.01 wieder aufgefüllt was ich kürzlich im AH Handel verkauft hatte.
Antwort auf Beitrag Nr.: 67.047.408 von Sven_Bonn am 17.02.21 08:22:26Ja, aber irgendwie geht es hier nur runter 🤔
Trading Spotlight
ein GLSI Move wäre ja nicht sooooooooooo schlecht.. Bin gespannt.. institutionelle Anleger sind nun ja reichlich da.. die Pipeline sieht super aus und es ist alles angerichtet für die nächsten Ergebnisse...
Mein persönliches Ziel für dieses Jahr habe ich mir mit 20 Euro gesetzt.
LG
Sven
Mein persönliches Ziel für dieses Jahr habe ich mir mit 20 Euro gesetzt.
LG
Sven
wow.. das ging ja nachbörslich sehr gut ab !!!
Baker Bros Investment hat massiv investiert:
https://newsfilter.io/a/e37796e0ae80e136f79e708e12558b13
Mal schauen, was noch geht.. :-)
LG
Sven
Baker Bros Investment hat massiv investiert:
https://newsfilter.io/a/e37796e0ae80e136f79e708e12558b13
Mal schauen, was noch geht.. :-)
LG
Sven
February 8, 2021
First Posted Date ICMJE February 12, 2021
Last Update Posted Date February 12, 2021
Estimated Study Start Date ICMJE June 2021
Estimated Primary Completion Date February 2023 (Final data collection date for primary outcome measure)
Current Primary Outcome Measures ICMJE
(submitted: February 11, 2021) Efficacy: Overall Response Rate (ORR) [ Time Frame: 2.5 Years ]
ORR is defined as incidence of complete responses or partial responses as assessed by RECIST v1.1
Original Primary Outcome Measures ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures ICMJE
(submitted: February 11, 2021)
Number of subjects with treatment -related adverse events (AEs), including serious adverse events (SAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [ Time Frame: 2.5 years ]
Determine if treatment with ADP-A2M4CD8 is safe and tolerable through assessment of adverse events (AEs) including Serious Adverse Events (SAEs)
Efficacy: Best overall response (BOR) [ Time Frame: 2.5 Years ]
Best Overall Response (BOR) is per RECIST V1.1.
Time to response (TTR) [ Time Frame: 2.5 years ]
For patients who are observed to respond to ADP-A2M4CD8, the time taken from date of infusion to achieve a partial response or complete response (TTR) is assessed.
Duration of Response (DoR) [ Time Frame: 2.5 years ]
For patients who are observed to respond to ADP-A2M4CD8, the DoR is the date of initial response (including confirmation) from date of infusion up until disease progression per RECIST v 1.1 or death.
Progression Free Survival (PFS) [ Time Frame: 2.5 years ]
PFS is assessed from date of infusion of ADP-A2M4CD8 up until the date of disease progression per RECIST v1.1 or death.
Overall Survival (OS) [ Time Frame: 15 years ]
OS is assessed from date of infusion of ADP-A2M4CD8 up until the date of patient death.
Invitro diagnostic (IVD) assay for screening [ Time Frame: 2.5 years ]
Development and validation of the MAGE-A4 antigen expression companion diagnostic assay
Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs [ Time Frame: 2.5 years ]
Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by flow cytometry
First Posted Date ICMJE February 12, 2021
Last Update Posted Date February 12, 2021
Estimated Study Start Date ICMJE June 2021
Estimated Primary Completion Date February 2023 (Final data collection date for primary outcome measure)
Current Primary Outcome Measures ICMJE
(submitted: February 11, 2021) Efficacy: Overall Response Rate (ORR) [ Time Frame: 2.5 Years ]
ORR is defined as incidence of complete responses or partial responses as assessed by RECIST v1.1
Original Primary Outcome Measures ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures ICMJE
(submitted: February 11, 2021)
Number of subjects with treatment -related adverse events (AEs), including serious adverse events (SAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [ Time Frame: 2.5 years ]
Determine if treatment with ADP-A2M4CD8 is safe and tolerable through assessment of adverse events (AEs) including Serious Adverse Events (SAEs)
Efficacy: Best overall response (BOR) [ Time Frame: 2.5 Years ]
Best Overall Response (BOR) is per RECIST V1.1.
Time to response (TTR) [ Time Frame: 2.5 years ]
For patients who are observed to respond to ADP-A2M4CD8, the time taken from date of infusion to achieve a partial response or complete response (TTR) is assessed.
Duration of Response (DoR) [ Time Frame: 2.5 years ]
For patients who are observed to respond to ADP-A2M4CD8, the DoR is the date of initial response (including confirmation) from date of infusion up until disease progression per RECIST v 1.1 or death.
Progression Free Survival (PFS) [ Time Frame: 2.5 years ]
PFS is assessed from date of infusion of ADP-A2M4CD8 up until the date of disease progression per RECIST v1.1 or death.
Overall Survival (OS) [ Time Frame: 15 years ]
OS is assessed from date of infusion of ADP-A2M4CD8 up until the date of patient death.
Invitro diagnostic (IVD) assay for screening [ Time Frame: 2.5 years ]
Development and validation of the MAGE-A4 antigen expression companion diagnostic assay
Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs [ Time Frame: 2.5 years ]
Time taken to achieve peak expansion of genetically engineered T-cells in PBMCs by flow cytometry
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) - NCT04752358
!!!!!
https://newsfilter.io/a/1e2880df1545a99a3de45bf1000e6282
https://clinicaltrials.gov/ct2/show/NCT04752358
:-) !!
!!!!!
https://newsfilter.io/a/1e2880df1545a99a3de45bf1000e6282
https://clinicaltrials.gov/ct2/show/NCT04752358
:-) !!
WICHTIG:
https://newsfilter.io/a/51f21a02af25a832c58868b8997c03f7
Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021
https://newsfilter.io/a/51f21a02af25a832c58868b8997c03f7
Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021
Durchsuchen
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived A
